Project: moleculaR -based, Data -driven drug REpurposing for bladder Cancer
| Acronym | ReDiRECt (Reference Number: 113726) |
| Duration | 01/07/2020 - 01/07/2023 |
| Project Topic | ReDiRECt targets to introduce in the pharmaceutical and biotechnology industry sector (the market) candidates for drug repurposing in bladder cancer (BC) (the products). An in silico drug repurposing based on the comparison of the molecular signature of BC against the molecular signature of drugs will be applied, followed by testing in disease models. The BC signature will be derived from integration of proteomics data with publicly available transcriptomics and literature- mined data. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 12 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Medizinische Universität Innsbruck | Partner | Austria |
| 2 | Mosaiques Diagnostics GmbH | Coordinator | Germany |
| 3 | Université du Luxembourg | Partner | Luxembourg |